



OPEN

Association between body mass index and prognosis of patients hospitalized with heart failure

Yuta Seko¹, Takao Kato^{1✉}, Takeshi Morimoto², Hidenori Yaku¹, Yasutaka Inuzuka³, Yodo Tamaki⁴, Neiko Ozasa¹, Masayuki Shiba¹, Erika Yamamoto¹, Yusuke Yoshikawa¹, Yugo Yamashita¹, Takeshi Kitai⁵, Ryoji Taniguchi⁶, Moritake Iguchi⁷, Kazuya Nagao⁸, Takafumi Kawai⁹, Akihiro Komasa¹⁰, Ryusuke Nishikawa¹¹, Yuichi Kawase¹², Takashi Morinaga¹³, Mamoru Toyofuku¹⁴, Yutaka Furukawa⁵, Kenji Ando¹³, Kazushige Kadota¹², Yukihito Sato⁶, Koichiro Kuwahara¹⁵ & Takeshi Kimura¹

The prognostic implications of very low body mass index (BMI) values remain unclear in patients with acute decompensated heart failure (ADHF). This study aimed to investigate the prognostic impact of BMI classification based on the World Health Organization criteria in patients with ADHF. Among 3509 patients with ADHF and available BMI data at discharge in 19 participating hospitals in Japan between October 2014 and March 2016, the study population was divided into five groups; (1) Severely underweight: BMI < 16 kg/m², (2) Underweight: BMI ≥ 16 kg/m² and < 18.5 kg/m², (3) Normal weight: BMI ≥ 18.5 kg/m² and < 25 kg/m², (4) Overweight: BMI ≥ 25 kg/m² and < 30 kg/m², (5) Obese: BMI ≥ 30 kg/m². The primary outcome measure was all-cause death. The median follow-up duration was 471 days, with 96.4% follow up at 1-year. The cumulative 1-year incidence of all-cause death was higher in underweight groups, and lower in overweight groups (Severely underweight: 36.3%, Underweight: 23.9%, Normal weight: 14.4%, Overweight: 7.9%, and Obese: 9.0%, $P < 0.001$). After adjusting confounders, the excess mortality risk remained significant in the severely underweight group (HR, 2.32; 95%CI, 1.83–2.94; $P < 0.001$), and in the underweight group (HR, 1.31; 95%CI, 1.08–1.59; $P = 0.005$) relative to the normal weight group, while the lower mortality risk was no longer significant in the overweight group (HR, 0.82; 95%CI, 0.62–1.10; $P = 0.18$) and in the obese group (HR, 1.09; 95%CI, 0.65–1.85; $P = 0.74$). Very low BMI was associated with a higher risk for one-year mortality after discharge in patients with ADHF.

Obesity, or a higher body mass index (BMI) is associated with an increased risk of death and cardiovascular events including heart failure (HF) in the general population^{1–3}. On the other hand, a higher BMI has been demonstrated to have a paradoxical association with a decreased risk of mortality in patients with HF^{4–8}. Previous studies have also demonstrated higher mortality rates in HF patients with a lower BMI^{4–8}. There is a global trend for progressive aging of HF patients^{9,10}. BMI values are much lower in elderly patients than in younger individuals, and the overlap of aging and low BMI has been most prominently seen in Japan¹¹. Although the

¹Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. ²Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan. ³Cardiovascular Medicine, Shiga General Hospital, Moriyama, Japan. ⁴Division of Cardiology, Tenri Hospital, Nara, Japan. ⁵Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan. ⁶Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan. ⁷Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan. ⁸Department of Cardiology, Osaka Red Cross Hospital, Osaka, Japan. ⁹Department of Cardiology, Kishiwada City Hospital, Osaka, Japan. ¹⁰Department of Cardiology, Kansai Electric Power Hospital, Osaka, Japan. ¹¹Department of Cardiology, Shizuoka General Hospital, Shizuoka, Japan. ¹²Department of Cardiology, Kurashiki Central Hospital, Okayama, Japan. ¹³Department of Cardiology, Kokura Memorial Hospital, Fukuoka, Japan. ¹⁴Department of Cardiology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan. ¹⁵Department of Cardiovascular Medicine, Shinshu University Graduate School of Medicine, Nagano, Japan. ✉email: tkato75@kuhp.kyoto-u.ac.jp




Figure 1. Study flowchart. *ADHF* acute decompensated heart failure, *BMI* body mass index, *KCHF* Kyoto Congestive Heart Failure.

association with low BMI and mortality in patients with HF has been confirmed, there is a paucity of data on the association between a severely low BMI at discharge and mortality in both chronic and acute decompensated HF (ADHF) patients across the world. Identifying the characteristics and prognosis of patients with a severely low BMI may be useful for the improvement of the management of HF, especially in elderly patients. In addition, the association between obesity and mortality or HF hospitalization is uncertain in the patients with HF in Japan because of the very small number of obese patients in Japan. Thus, we aimed to examine the association between the BMI status at discharge based on the World Health Organization (WHO) standard and the 1-year mortality or HF hospitalization, along with the cardiovascular and non-cardiovascular death, using a large contemporary all-comer registry of patients with ADHF hospitalization in Japan.

Method

Study design, setting, and population. The Kyoto Congestive Heart Failure (KCHF) registry is a physician-initiated, prospective, observational, multicenter cohort study that enrolled consecutive patients who were hospitalized for ADHF for the first time between 1 October 2014 and 31 March 2016 without any exclusion criteria. These patients were admitted into 19 secondary and tertiary hospitals, including rural and urban, large and small institutions, throughout Japan. The overall design of the KCHF study and patient enrolment has been previously described in detail^{11–16}.

We enrolled consecutive patients with ADHF as defined by the modified Framingham criteria admitted to the participating centers, who underwent heart failure-specific treatment involving intravenous drugs within 24 h of hospital presentation. Patient records were anonymized before analysis. Data analysis was conducted from February 2020 to March 2020.

Among 4056 patients enrolled in the KCHF registry, the current study population consisted of 3509 patients who were discharged alive and whose BMI was calculated at discharge, excluding 271 patients who died during the index hospitalization, 228 patients whose BMI at discharge was not available (Supplementary Table 1), and 57 patients were excluded because of missing follow-up data after discharge. (Fig. 1). We stratified the patients into 5 groups according to BMI at discharge based on the WHO standard¹⁷; (1) Severely underweight: BMI < 16 kg/m², (2) Underweight: BMI ≥ 16 kg/m² and < 18.5 kg/m², (3) Normal weight: BMI ≥ 18.5 kg/m² and < 25 kg/m², (4) Overweight: BMI ≥ 25 kg/m² and < 30 kg/m², and (5) Obese: BMI ≥ 30 kg/m².

Definitions. We collected data on patient demographics, medical history, underlying heart disease, pre-hospital activities, socioeconomic status, signs, symptoms, medications, laboratory tests at hospital presentation, electrocardiogram, echocardiography during hospitalization^{11,13,14}.

The detailed definitions of baseline patient characteristics were as follows: BMI was calculated as weight in kilograms divided by the square of the height in meters¹⁷. Anemia was defined using the WHO criteria (hemoglobin < 12.0 g/dL in women and < 13.0 g/dL in men). Chronic kidney disease was defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m² at admission. Renal dysfunction was defined as estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² based on the chronic kidney disease grades¹¹. HF was classified according to left ventricular ejection fraction (LVEF), as HF with preserved LVEF (LVEF ≥ 50%), HF with mid-range LVEF (40% ≤ LVEF < 50%), and HF with reduced LVEF (LVEF < 40%)¹⁸.

Outcomes. One-year clinical follow-up data with an allowance of one month, were collected in October 2017. The attending physicians or research assistants at each participating hospital collected clinical events after

the index of hospitalization from hospital charts or by contacting patients, their relatives or their referring physicians with consent.

The primary outcome measure for the present analysis was all-cause death after discharge from the index hospitalization. The secondary outcome measures included cardiovascular death, non-cardiovascular death, and HF hospitalization after discharge from the index hospitalization. The causes of death were classified according to the VARC (Valve Academic Research Consortium) definitions¹⁹ and were adjudicated by a clinical event committee^{11–14}.

Statistical analysis. We evaluated BMI as a categorical variable (severely underweight, underweight, normal weight [reference], overweight, and obese).

The categorical variables are presented as numbers and percentages. The continuous variables are expressed as mean and standard deviation (SD) or median with interquartile range (IQR). Comparisons among 5 groups were performed using a 1-way ANOVA or Kruskal–Wallis test for continuous variables and the chi-square test for categorical variables. We regarded the date of discharge as time zero for clinical follow-up. We compared the baseline characteristics and clinical outcomes on the basis of BMI status at discharge from the index hospitalization.

The cumulative incidences of the clinical events during 1-year after discharge were estimated using the Kaplan–Meier method with the intergroup differences assessed by the log-rank test. To estimate the risk of each BMI group with normal weight group as the reference, a multivariable Cox proportional hazards model was developed for the primary and secondary outcome measures adjusting for the confounders. We included the following 24 clinically relevant risk-adjusting variables into the model: age as a continuous variable, sex, LVEF < 40% by echocardiography, variables related to medical history (etiology of HF hospitalization associated with acute coronary syndrome, previous HF hospitalization, atrial fibrillation or flutter, hypertension, diabetes mellitus, previous myocardial infarction, previous stroke, current smoking, chronic lung disease and malignant neoplasm), variables related to comorbidities (living alone, ambulatory, systolic blood pressure < 90 mmHg, heart rate < 60 bpm, eGFR < 30 ml/min/1.73 m², albumin < 3.0 g/dL, sodium < 135 mEq/L, and anemia), and medications at discharge (angiotensin converting enzyme inhibitors [ACEIs] or angiotensin II receptor blockers [ARBs], β -blockers, and tolvaptan), consistent with our previous reports^{13,14,16}. The continuous variables were dichotomized by clinically meaningful reference values or median values. The results were expressed as a hazard ratio (HR) and 95% confidence intervals (CIs). In the post hoc subgroup analysis we evaluated the interaction between the 6 subgroup factors (age $\geq$ 80 years, sex, diabetes mellitus, eGFR < 30 ml/min/1.73 m², LVEF < 40%, and residual edema at discharge) and the effect of BMI classification on the primary outcome measure. In the sensitivity and additional analyses, we used several classifications regarding BMI. The detailed methods were described in Supplementary methods. All statistical analyses were Y.S. and T.K. by 2 physicians (Y.S. and T.K.) and a statistician (T.M.) using JMP 14. All the reported *P* values were two tailed, and the level of statistical significance was set at *P* < 0.05.

Ethics. The investigation conformed with the principles outlined in the Declaration of Helsinki. The study protocol was approved by the ethical committees of the Kyoto University Hospital (local identifier: E2311) and each participating hospital. A waiver of written informed consent from each patient was granted by the institutional review boards of Kyoto University and each participating center as the study met the conditions of the Japanese ethical guidelines for epidemiological study^{20,21}.

Results

Baseline characteristics. The mean and median BMI value at discharge were 21.4 ± 4.2 kg/m² and 20.9 (IQR: 18.5–23.6) kg/m², respectively, and ranged from 10.5 to 55.9 kg/m² (Supplementary Fig. 1). We categorized the patients into 5 groups according to BMI at discharge: Severely underweight: N = 238 (6.8%), Underweight: N = 632 (18.0%), Normal weight: N = 2064 (58.8%), Overweight: N = 448 (12.8%), and Obese: N = 127 (3.6%) (Fig. 1). Patients with lower BMI values were older and more often women, and were more likely to have malignant neoplasm, dementia, higher BNP levels, hypoalbuminemia, and anemia (Table 1). On the other hand, patients with higher BMI values were more likely to have hypertension, diabetes mellitus, dyslipidemia, previous myocardial infarction, and current smoking, and were more likely to be ambulatory (Table 1). Patients with higher BMI values more often receive angiotensin converting enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARB) and β -blocker at discharge than those with lower BMI values.

Clinical outcomes. The median follow-up duration was 471 (IQR: 378–666) days, with a 96.4% follow up rate at 1 year. The cumulative 1-year incidence of all-cause death was higher in underweight groups, and lower in overweight groups (Severely underweight: 36.3%, Underweight: 23.9%, Normal weight: 14.4%, Overweight: 7.9%, and Obese: 9.0%, *P* < 0.001) (Fig. 2A). After adjusting for confounders, the excess risk for all-cause death remained significant in the severely underweight group (HR, 2.32; 95%CI, 1.83–2.94; *P* < 0.001), and in the underweight group (HR, 1.31; 95%CI, 1.08–1.59; *P* = 0.005) relative to the normal weight group, while the lower risk for all-cause death was no longer significant in the overweight group (HR, 0.82; 95%CI, 0.62–1.10; *P* = 0.18) and the excess risk for all-cause death was no significant in the obese group (HR, 1.09; 95%CI, 0.65–1.85; *P* = 0.74) (Fig. 3). The cumulative 1-year incidence of cardiovascular death was also higher in underweight groups, and lower in overweight groups (Severely underweight: 22.7%, Underweight: 14.8%, Normal weight: 8.8%, Overweight: 5.2%, and Obese: 7.5%, *P* < 0.001) (Fig. 2B). After adjusting for confounders, the excess risk for cardiovascular death remained significant in the severely underweight group (HR, 2.23; 95%CI, 1.64–3.03; *P* < 0.001), relative to the normal weight group, while the excess risk for cardiovascular death was no longer significant in the underweight group (HR, 1.23; 95%CI, 0.96–1.58; *P* = 0.10) and the obese group (HR, 1.27; 95%CI,

Variables	Total (N = 3509)	Severely underweight (N = 238)	Underweight (N = 632)	Normal weight (N = 2064)	Overweight (N = 448)	Obese (N = 127)	P value	Total N
Clinical characteristic								
Age*, years	77.2 ± 12.0	83.2 ± 9.5	79.9 ± 10.7	77.6 ± 11.2	72.5 ± 13.0	64.2 ± 16.9	< 0.001	3509
Age ≥ 80 years	1770 (50.4)	179 (75.2)	374 (59.2)	1035 (50.2)	154 (34.4)	28 (22.1)	< 0.001	3509
Women*	1538 (43.8)	155 (65.1)	333 (52.7)	825 (40.0)	167 (37.3)	58 (45.7)	< 0.001	3509
Body weight, kg at admission	56.7 ± 14.6	39.6 ± 6.9	45.9 ± 7.8	56.7 ± 10.0	70.8 ± 11.9	91.0 ± 20.0	< 0.001	3481
BMI at admission	22.9 ± 4.5	16.6 ± 1.9	19.1 ± 1.8	22.9 ± 2.3	28.2 ± 2.3	35.7 ± 4.9	< 0.001	3481
Body weight, kg at discharge	52.8 ± 13.5	35.3 ± 4.8	41.8 ± 5.7	53.1 ± 8.6	67.2 ± 10.0	85.7 ± 17.5	< 0.001	3509
BMI at discharge	21.4 ± 4.2	14.9 ± 0.9	17.4 ± 0.7	21.4 ± 1.8	26.7 ± 1.3	33.7 ± 4.0	< 0.001	3509
Etiology							< 0.001	3509
Ischemic	1147 (32.7)	54 (22.7)	178 (28.2)	698 (33.8)	182 (40.6)	35 (27.6)		
Associated with ACS*	194 (5.5)	6 (2.5)	22 (3.5)	124 (6.0)	36 (8.0)	6 (4.7)		
Not associated with ACS	953 (27.2)	48 (20.2)	156 (24.7)	574 (27.8)	146 (32.6)	29 (22.8)		
Hypertensive	870 (24.8)	58 (24.4)	123 (19.5)	518 (25.1)	129 (28.8)	42 (33.1)		
Valvular heart disease	683 (19.5)	71 (29.8)	173 (27.4)	370 (17.9)	53 (11.8)	16 (12.6)		
Cardiomyopathy	534 (15.2)	33 (13.9)	103 (16.3)	314 (15.2)	62 (13.8)	22 (17.3)		
Dilated cardiomyopathy	386 (11.0)	23 (9.7)	69 (10.9)	226 (11.0)	50 (11.2)	18 (14.2)		
Arrhythmia-related	164 (4.7)	12 (5.0)	32 (5.1)	103 (5.0)	13 (2.9)	4 (3.2)		
Medical history								
Heart failure hospitalization*	1272 (36.8)	101 (42.6)	247 (39.5)	714 (35.2)	160 (36.3)	50 (40.0)	0.09	3456
Hypertension*	2551 (72.7)	151 (63.5)	411 (65.0)	1538 (74.5)	358 (79.9)	93 (73.2)	< 0.001	3509
Diabetes*	1327 (37.8)	38 (16.0)	155 (24.5)	809 (39.2)	245 (54.7)	80 (63.0)	< 0.001	3509
Dyslipidemia	1393 (39.7)	65 (27.3)	197 (31.2)	827 (40.1)	233 (52.0)	71 (55.9)	< 0.001	3509
Atrial fibrillation or flutter*	1477 (42.1)	104 (43.7)	272 (43.0)	867 (42.0)	189 (42.2)	45 (35.4)	0.59	3509
VT/VF	147 (4.2)	6 (2.5)	29 (4.6)	84 (4.1)	21 (4.7)	7 (5.5)	0.59	3509
Previous myocardial infarction*	806 (23.0)	38 (16.0)	134 (21.2)	486 (23.6)	123 (27.5)	25 (19.7)	0.007	3509
Prior PCI or CABG	924 (26.3)	42 (17.7)	141 (22.3)	555 (26.9)	153 (34.2)	33 (26.0)	< 0.001	3509
Previous stroke*	548 (15.6)	32 (13.5)	106 (16.8)	331 (16.0)	68 (15.2)	11 (8.7)	0.17	3509
Current smoking*	442 (12.8)	25 (10.6)	63 (10.2)	255 (12.6)	76 (17.2)	23 (18.1)	0.003	3450
Chronic lung disease*	463 (13.2)	34 (14.3)	93 (14.7)	266 (12.9)	52 (11.6)	18 (14.2)	0.59	3509
COPD	289 (8.2)	27 (11.3)	70 (11.1)	163 (7.9)	24 (5.4)	5 (3.9)	0.001	3509
Liver cirrhosis	46 (1.3)	0 (0)	3 (0.5)	36 (1.7)	5 (1.1)	2 (1.6)	0.04	3509
Malignancy*	507 (14.4)	45 (18.9)	109 (17.3)	288 (14.0)	57 (12.7)	8 (6.3)	0.003	3509
Dementia	569 (16.2)	69 (29.0)	131 (20.7)	324 (15.7)	37 (8.3)	8 (6.3)	< 0.001	3509
Social background on admission								
Poor medical adherence	586 (16.7)	35 (14.7)	113 (17.9)	334 (16.2)	84 (18.8)	20 (15.8)	0.53	3509
Living alone*	755 (21.5)	50 (21.0)	140 (22.2)	422 (20.5)	112 (25.0)	31 (24.4)	0.25	3509
Employed	484 (13.8)	11 (4.6)	60 (9.5)	269 (13.0)	102 (22.8)	42 (33.1)	< 0.001	3509
Public financial assistance	207 (5.9)	13 (5.5)	39 (6.2)	116 (5.6)	31 (6.9)	8 (6.3)	0.86	3509
Daily life activities							< 0.001	3475
Ambulatory*	2837 (81.6)	161 (68.2)	475 (76.2)	1709 (83.7)	381 (85.4)	111 (87.4)		
Use of wheelchair (outdoor only)	251 (7.2)	16 (6.8)	53 (8.5)	147 (7.2)	28 (6.3)	7 (5.5)		
Use of wheelchair (outdoor and indoor)	297 (8.5)	45 (19.1)	72 (11.6)	148 (7.2)	29 (6.5)	3 (2.4)		
Bedridden	90 (2.6)	14 (5.9)	23 (3.7)	39 (1.9)	8 (1.8)	6 (4.7)		
Vital signs at presentation								
Heart rate, bpm	96.0 ± 27.6	97.0 ± 26.0	94.8 ± 27.0	96.5 ± 27.9	94.5 ± 27.8	96.7 ± 28.9	0.27	3488
< 60 beats/min*	232 (6.7)	15 (6.3)	43 (6.9)	131 (6.4)	33 (7.4)	10 (7.9)	0.90	3488
Systolic BP, mmHg	148.3 ± 34.9	142.5 ± 31.5	144.5 ± 34.5	148.9 ± 35.0	153.5 ± 35.5	149.7 ± 36.8	< 0.001	3500
Continued								

Variables	Total (N = 3509)	Severely underweight (N = 238)	Underweight (N = 632)	Normal weight (N = 2064)	Overweight (N = 448)	Obese (N = 127)	P value	Total N
Systolic BP < 90 mm Hg*	87 (2.5)	5 (2.1)	23 (3.7)	50 (2.4)	7 (1.6)	2 (1.6)	0.22	3500
Diastolic BP, mmHg	85.3 ± 23.8	80.0 ± 19.7	83.7 ± 24.6	85.7 ± 23.7	88.0 ± 24.5	86.6 ± 25.5	< 0.001	3494
Rhythms at presentation							0.58	3509
Sinus Rhythm	1964 (56.0)	145 (60.9)	355 (56.2)	1140 (55.2)	246 (54.9)	78 (61.4)		
Atrial fibrillation or flutter	1271 (36.2)	76 (31.9)	235 (37.2)	747 (36.2)	172 (38.4)	41 (32.3)		
NYHA class III or IV	3042 (86.9)	216 (90.8)	556 (88.3)	1760 (85.5)	393 (87.9)	117 (92.9)	0.02	3499
Test results at admission								
LVEF, %	46.2 ± 16.2	45.6 ± 16.7	45.6 ± 16.3	46.1 ± 16.0	48.3 ± 16.6	45.4 ± 17.3	0.048	3435
LVEF classification							0.27	3498
HFrEF (LVEF < 40%)*	1321 (37.8)	94 (39.5)	239 (37.9)	788 (38.3)	148 (33.2)	52 (41.3)		
HFmrEF (LVEF 40%–49%)	659 (18.8)	42 (17.7)	121 (19.2)	400 (19.5)	78 (17.5)	18 (14.3)		
HFpEF (LVEF ≥ 50%)	1518 (43.4)	102 (42.9)	271 (43.0)	869 (42.3)	220 (49.3)	56 (44.4)		
BNP, pg/ml	710 (387–1251)	907 (508–1663)	935 (512–1548)	711 (412–1242)	461 (269–784)	384 (214–777)	< 0.001	3108
NT-proBNP, pg/ml	5416 (2631–11,955)	11,732 (4772–23,213)	8530 (3836–16,947)	5314 (2678–10,746)	4036 (1982–6293)	2388 (1055–5361)	< 0.001	614
Serum creatinine, mg/dl	1.48 ± 1.28	1.24 ± 0.84	1.33 ± 1.04	1.54 ± 1.37	1.52 ± 1.36	1.43 ± 1.06	< 0.001	3503
eGFR, ml/min/1.73m ²	46.3 ± 23.4	48.6 ± 25.1	48.0 ± 24.9	45.1 ± 22.7	47.1 ± 23.2	48.8 ± 23.9	0.07	3503
< 60 ml/min/1.73m ²	2588 (73.9)	172 (72.9)	446 (70.7)	1559 (75.6)	320 (71.4)	91 (71.7)	0.07	3503
< 30 ml/min/1.73m ² *	921 (26.3)	59 (25.0)	165 (26.2)	550 (26.7)	121 (27.0)	26 (20.5)	0.61	3503
Blood urea nitrogen, mg/dl	28.3 ± 16.1	29.6 ± 15.5	29.1 ± 16.0	28.5 ± 16.4	25.6 ± 14.4	26.6 ± 17.7	< 0.001	3498
Albumin, g/dl	3.49 ± 0.49	3.27 ± 0.50	3.39 ± 0.45	3.52 ± 0.48	3.62 ± 0.50	3.56 ± 0.50	< 0.001	3408
< 3.0 g/dl*	438 (12.9)	53 (22.9)	95 (15.5)	239 (12.0)	38 (8.6)	13 (10.7)	< 0.001	3408
Sodium, mEq/l	139.2 ± 4.1	138.7 ± 4.4	138.9 ± 4.7	139.2 ± 4.1	139.8 ± 3.5	139.1 ± 4.2	0.005	3498
< 135 mEq/l*	405 (11.6)	32 (13.6)	102 (16.2)	221 (10.7)	35 (7.8)	15 (11.9)	< 0.001	3498
Hemoglobin, g/dl	11.6 ± 2.4	10.9 ± 2.0	11.1 ± 2.2	11.6 ± 2.3	12.2 ± 2.5	12.7 ± 2.5	< 0.001	3503
Anemia*	2299 (65.6)	180 (75.6)	470 (74.5)	1337 (64.9)	251 (56.0)	61 (48.0)	< 0.001	3503
CRP, mg/dL	1.99 ± 3.58	2.27 ± 3.82	2.06 ± 3.41	2.02 ± 3.75	1.67 ± 2.94	1.72 ± 3.13	0.59	3422
Medication at discharge								
ACEI or ARB*	2058 (58.6)	103 (43.3)	335 (53.0)	1227 (59.5)	305 (68.1)	88 (69.3)	< 0.001	3509
β blocker*	2376 (67.7)	125 (52.5)	400 (63.3)	1426 (69.1)	327 (73.0)	98 (77.2)	< 0.001	3509
MRA	1589 (45.3)	114 (47.9)	314 (49.7)	895 (43.4)	196 (43.8)	70 (55.1)	0.007	3509
Loop diuretics	2865 (81.6)	198 (83.2)	520 (82.3)	1678 (81.3)	358 (79.9)	111 (87.4)	0.35	3509
Tolvaptan*	377 (10.7)	17 (7.1)	67 (10.6)	239 (11.6)	34 (7.6)	20 (15.8)	0.01	3509
Congestion at discharge								
Edema	419 (12.3)	28 (12.3)	55 (9.1)	248 (12.4)	56 (12.9)	32 (25.4)	< 0.001	3399
Pulmonary congestion	270 (7.8)	23 (9.8)	50 (8.1)	157 (7.7)	25 (5.6)	15 (11.9)	0.12	3457
Jugular venous distention	224 (6.6)	15 (6.6)	37 (6.1)	134 (6.7)	25 (5.8)	13 (10.3)	0.48	3377

Table 1. Baseline characteristics of the study subjects and transthoracic echocardiography results of the patients. Values are number (%), mean ± SD, or median (interquartile range). P values were calculated using the chi square test or Fisher's exact test for categorical variables, and 1-way ANOVA or Kruskal–Wallis test for continuous variables. *Risk-adjusting variables selected for the Cox proportional hazard models. Chronic kidney disease was defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m². Renal dysfunction was defined as estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² based on the chronic kidney disease grades. Anemia was defined using the World Health Organization criteria (hemoglobin < 12.0 g/dl in women and < 13.0 g/dl in men). ACEI angiotensin-converting enzyme inhibitor, ACS acute coronary syndrome, ARB angiotensin-receptor blocker, BNP brain-type natriuretic peptide, BMI body mass index, BP blood pressure, eGFR estimated glomerular filtration rate, HFmrEF heart failure with mid-range ejection fraction, HFpEF heart failure with preserved ejection fraction, HFrEF heart failure with reduced ejection fraction, LVEF left ventricular ejection fraction, NT-pro BNP N-terminal-pro brain-type natriuretic peptide, NYHA New York Heart Association.




Figure 2. Kaplan–Meier curves for the primary and secondary outcome measures. (A) All-cause death (B) Cardiovascular death (C) Non-cardiovascular death (D) HF hospitalization. HF heart failure.




Figure 3. Forrest plots for the adjusted hazard ratios of each BMI category for the clinical outcome measures. BMI, body mass index; CI, confidence interval; HF, heart failure; HR, hazard ratio.

0.69–2.36; $P=0.44$) and the lower risk for cardiovascular death was no longer significant in the overweight group (HR, 0.75; 95%CI, 0.51–1.10; $P=0.15$) (Fig. 3). The cumulative 1-year incidence of non-cardiovascular death was also higher in underweight groups, and lower in overweight groups (Severely underweight: 17.6%, Underweight: 10.7%, Normal weight: 6.1%, Overweight: 2.8%, and Obese: 1.7%, $P<0.001$) (Fig. 2C). After adjusting for confounders, the excess risk for non-cardiovascular death remained significant in the severely underweight group (HR, 2.43; 95%CI, 1.67–3.54; $P<0.001$), and in the underweight group (HR, 1.46; 95%CI, 1.08–1.97; $P=0.01$) relative to the normal weight group, while the lower risk for non-cardiovascular death was no longer significant in the overweight group (HR, 0.93; 95%CI, 0.60–1.43; $P=0.73$), and in the obese group (HR, 0.78; 95%CI, 0.29–2.13; $P=0.63$) (Fig. 3). The cumulative 1-year incidence of HF hospitalization decreased with increasing BMI (Severely underweight: 30.0%, Underweight: 24.2%, Normal weight: 24.2%, Overweight: 21.6%, and Obese: 18.8%, $P<0.001$) (Fig. 2D). After adjusting for confounders, the risk for HF hospitalization was not significantly different across the 5 groups stratified by BMI (Fig. 3).

Subgroup analysis. The BMI at discharge was significantly lower in the subgroups of women, and patients without edema at discharge than those without (Supplementary Table 2). There was no significant interaction between the subgroup factors and the effect of the each BMI group relative to normal weight group on all-cause death (Fig. 4).

Sensitivity analysis using modified classification for Asian populations. When we used the modified classification in which the 16, 18.5, 23, and 27.5 kg/m² cutoffs were used (Supplementary Table 3), the results (Supplementary Figs. 2 and 3) were mostly consistent with the main analysis. BMIs of <16 kg/m² were associated with increased risk, whereas BMIs of ≥ 23 kg/m² but <27.5 kg/m² were associated with decreased risk of all-cause death and cardiovascular death in patients as compared with BMIs of ≥ 18.5 kg/m² but <23 kg/m² (Supplementary Figs. 2 and 3).

Additional analysis using BMI quartiles at discharge. When we divided the participants into BMI quartiles (Supplementary Table 4), the results (Supplementary Figs. 4 and 5) were mostly consistent with the main analysis. The lowest quartile was associated with increased risk of all-cause death, cardiovascular death, and non-cardiovascular death in patients as compared with BMIs of ≥ 20.9 kg/m² but <23.6 kg/m² (Supplementary Figs. 4 and 5). Highest quartile (BMI ≥ 23.6 kg/m²) was not associated with increased or decreased risks of all-cause death, cardiovascular death, and non-cardiovascular death in patients as compared with BMIs of ≥ 20.9 kg/m² but <23.6 kg/m² (Supplementary Figs. 4 and 5).

Prognostic implications of BMI at admission. When we stratified the patients into 5 groups according to BMI at admission based on the WHO classification (Supplementary Table 5, Supplementary Fig. 6), the results were mostly consistent with the main analysis. The excess risk for all-cause death remained significant in the severely underweight group and in the underweight group, whereas overweight was associated with decreased risk of all-cause death and cardiovascular death in patients compared to normal weight (Supplementary Figs. 7 and 8).

Discussion

The main findings of this study were as follows; (1) Lower BMI, especially severely underweight status, was associated with increased mortality in patients after discharge with HF; (2) Overweight and obesity based on WHO classifications were not associated with increased or decreased risk of death in patients compared to normal weight status; (3) The risk for HF hospitalization was not affected by BMI status.

The association of BMI and prognosis in patients with HF has long been investigated. However, there is only one report on the prognostic significance of a severely underweight status in patients with HF. Matsushita et al. reported a severely low BMI was associated with mortality in the patients with ADHF, but the number of patients with a severely underweight BMI were limited²² and the risk for death compared to that of normal weight status was unclear²². Using the large database in Japan, we showed that the severely underweight status was associated with all-cause, cardiovascular, and non-cardiovascular death. Our results are consistent with previous studies, which have shown a lower BMI is associated with a higher risk of death^{4,5,7,8,23}. The classification of BMI did not influence the risk of hospitalization for HF in multivariable analyses, which is consistent with the results of the DIG and CHARM sub-studies^{5,23}. The 1-year mortality after hospital discharge for ADHF is relatively low in the present study and ranged from 16.5% (cumulative 1-year mortality) to 22.2% in other Japanese studies²⁴ as compared with that in the United States²⁵, despite that older patients were enrolled in the Japanese registries. This might be due to the differences in ethnicity, HF etiology, and enrollment timeframe. Despite these differences, the prognostic influence of low BMI was observed across studies worldwide.

The mechanistic link between underweight status and poor outcome in patients with HF has been proposed. A lower BMI reflects a decrease in skeletal muscle, implying the associated malnutrition and inflammation^{17,26,27}. In fact, both the LVEF and NYHA status at presentation were not different among the BMI statuses. The albumin and hemoglobin levels were incrementally lower in the underweight groups. A reduction in food intake, gastrointestinal abnormalities, immunological and neurohormonal activation as well as an imbalance between anabolic and catabolic processes may be important mechanisms to understand these conditions^{26–29}. After adjusting for confounders such as age, sex, and the presence of anemia, the association between being underweight and a poor prognosis remained significant.

In our study, the mortality was lowest in patients with an overweight status, followed by those with an obese status, although there was no significant difference from patients with a normal weight status based on the




Figure 4. Subgroup analyses for the primary outcome measure (all-cause death). *BMI* body mass index, *CI* confidence interval, *eGFR* estimated glomerular filtration rate, *HR* hazard ratio, *LVEF* left ventricular ejection fraction.

WHO classifications^{30,31}. The patients in the overweight and obese groups were younger, had more metabolic diseases and decreased levels of BNP, and were more likely to be administered with an ACE-I/ARB or β -blocker. Low mortality rates in patients with higher BMI might be related to a greater metabolic reserve against stress³², a reduced cardiac sympathetic activity³³, an attenuated neurohormonal response³⁴, and a lower inflammatory cytokine levels, and lesser catabolic-anabolic imbalance³⁵.

In the theory of obesity paradox, having a larger BMI is associated with better outcomes; however, many of previous studies stratified patients into two groups for comparisons^{36–38}. In other studies, risk for all-cause death was lowest in obese patients ($\text{BMI} \geq 30 \text{ kg/m}^2$)^{2,7}. In contrast, a sub-study of CHARM trial reported that patients with $\text{BMI} \geq 35 \text{ kg/m}^2$ tended to show a worse prognosis⁵. Nagarajan et al. from Cleveland Clinic HF program demonstrated a poor prognosis in very obese patients ($\text{BMI} \geq 40 \text{ kg/m}^2$) with advanced HF³⁹. In the present study, the effect of higher BMI on mortality was inconclusive mainly due to small number of patients with higher BMI. The prevalence of overweight and obese HF patients was much lower than reports in previous studies based on randomized trials in Western countries⁵ and previous studies from Japan conducted in 2004⁴⁰ and 2007³⁶. The differences in patient backgrounds may be derived from the style of the study and the countries and periods of enrollment, focusing on the increase in aging patients with ADHF. The risk of all-cause death in obese patients was also inconclusive, but that in overweight patients became significant when we adopted the cutoffs for the Asian population. In Japan, the cutoff BMI is authorized by the guidelines of the Japan Society for the Study of Obesity and is basically identical to the WHO classification^{30,31}. Defining the ideal BMI values in Japanese patient with ADHF is beyond the scope of the present study, and further studies are required to validate the cutoff BMI in Japan. Ideal body weight in patients with HF should be set individually and we should take ethnicity as well as comorbidities in consideration. Admission BMI was also associated with prognosis, even recognizing the setback of congestion. This result was consistent with the subgroup analysis stratified with or without edema at discharge. Considering the prognostic impact of BMI at admission and discharge, the evaluation of BMI is always critically important for the assessment of patients with ADHF. However, the BMI at admission can be more easily changed through the treatment for ADHF. In the present study, the mean difference between the BMIs at admission and discharge was 1.5 kg/m^2 (Table 1). Thus, the BMI at discharge would be a more reliable marker for patients with ADHF. Our study will be useful to understand the pathophysiology of ADHF and patients' conditions, and to evaluate the prognosis of patients with ADHF. When the BMI of a given patient is severely low, special attention should be paid to the worsening of HF and non-cardiovascular diseases. Future research would be warranted to identify and promote achieving the optimal BMI in individual patients.

Limitations. This study had several limitations. First, we could not determine the body weight at discharge was an optimal body weight without congestion in a given patient. Although the body weight at discharge was decreased compared to that at admission, a substantial proportion of patients had residual edema at discharge. Second, serum levels of cytokines, catecholamines, and renin and aldosterone were not collected. Thus, we can only speculate on the mechanistic link between the low BMI and poor outcome based on the available data in the present study. Third, residual unmeasured confounding factors could affect the results even after extensive adjustment. Due to lots of potential confounders, the conclusion should be treated with caution. Fourth, several subgroup analyses have a risk for multiple comparisons as well as a small sample size with low statistical power. Fifth, a selection bias might have been present. The patients with unavailable BMI data included older patients with anemia and hypoalbuminemia, and low ambulatory status. The lack of BMI data may be due to the patients' non-ambulatory status. The characteristics of the patients with unavailable BMI data were similar to those of underweight or severely underweight patients. The non-ambulatory patients showed worse outcomes¹⁶; thus, excluding these patients may not change the result of this study. Sixth, owing to the short-term follow-up, the causal link between BMI and outcome is unclear. Further research studies are needed to clarify the causal link.

Conclusion

Very low BMI was associated with a higher risk for one-year mortality after discharge in patients with ADHF.

Received: 16 June 2020; Accepted: 21 September 2020

Published online: 07 October 2020

References

1. Calle, E. E., Thun, M. J., Petrelli, J. M., Rodriguez, C. & Heath, C. W. Jr. Body-mass index and mortality in a prospective cohort of US adults. *N. Engl. J. Med.* **341**(15), 1097–1105. <https://doi.org/10.1056/NEJM199910073411501> (1999).
2. Kenchaiah, S. et al. Obesity and the risk of heart failure. *N. Engl. J. Med.* **347**, 305–313. <https://doi.org/10.1056/NEJMoa020245> (2002).
3. Levitan, E. B., Yang, A. Z., Wolk, A. & Mittleman, M. A. Adiposity and incidence of heart failure hospitalization and mortality: a population-based prospective study. *Circ. Heart Fail.* **2**, 202–208. <https://doi.org/10.1161/CIRCHEARTFAILURE.108.794099> (2009).
4. Fonarow, G. C. et al. An obesity paradox in acute heart failure: analysis of body mass index and in-hospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. *Am. Heart J.* **153**, 74–81. <https://doi.org/10.1016/j.ahj.2006.09.007> (2007).
5. Kenchaiah, S. et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. *Circulation* **116**, 627–636. <https://doi.org/10.1161/CIRCULATIONAHA.106.679779> (2007).
6. Lavie, C. J. et al. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. *JACC Heart Fail.* **1**, 93–102. <https://doi.org/10.1016/j.jchf.2013.01.006> (2013).

7. Shah, R. *et al.* Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox. *J. Am. Coll. Cardiol.* **63**, 778–785. <https://doi.org/10.1016/j.jacc.2013.09.072> (2014).
8. Sharma, A. *et al.* Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. *Am. J. Cardiol.* **115**, 1428–1434. <https://doi.org/10.1016/j.amjcard.2015.02.024> (2015).
9. Zhou, B. F. *et al.* Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late 1990s: the INTERMAP study. *J. Hum. Hypertens.* **17**, 623–630. <https://doi.org/10.1038/sj.jhh.1001605> (2003).
10. Filippatos, G. *et al.* Global differences in characteristics, precipitants, and initial management of patients presenting with acute heart failure. *JAMA Cardiol.* <https://doi.org/10.1001/jamacardio.2019.5108> (2020).
11. Yaku, H. *et al.* Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan- observations from the prospective, multicenter kyoto congestive heart failure (KCHF) registry. *Circ. J.* **82**, 2811–2819. <https://doi.org/10.1253/circj.CJ-17-1386> (2018).
12. Yamamoto, E. *et al.* Kyoto Congestive Heart Failure (KCHF) study: rationale and design. *ESC Heart Fail.* **4**, 216–223. <https://doi.org/10.1002/ehf2.12138> (2017).
13. Kanae, S. *et al.* Association of previous hospitalization for heart failure with increased mortality in patients hospitalized for acute decompensated heart failure. *Circ. Rep.* **1**, 517–524 (2019).
14. Yaku, H. *et al.* Association of mineralocorticoid receptor antagonist use with all-cause mortality and hospital readmission in older adults with acute decompensated heart failure. *JAMA Netw. Open* **2**, e195892. <https://doi.org/10.1001/jamanetworkopen.2019.5892> (2019).
15. Kato, T. *et al.* Association with controlling nutritional status (CONUT) score and in-hospital mortality and infection in acute heart failure. *Sci. Rep.* **10**, 3320. <https://doi.org/10.1038/s41598-020-60404-9> (2020).
16. Yaku, H. *et al.* Risk factors and clinical outcomes of functional decline during hospitalisation in very old patients with acute decompensated heart failure: an observational study. *BMJ Open* **10**, e032674. <https://doi.org/10.1136/bmjopen-2019-032674> (2020).
17. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organization technical report series. 1995;854:1–452.
18. Ponikowski, P. *et al.* 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur. J. Heart Failure* **18**, 891–975. <https://doi.org/10.1002/ehf2.592> (2016).
19. Kappetein, A. P. *et al.* Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *J. Am. Coll. Cardiol.* **60**, 1438–1454. <https://doi.org/10.1016/j.jacc.2012.09.001> (2012).
20. Ministry of Education, Culture, Sports, Science and Technology Ministry of Health, Labour and Welfare. Ethical guidelines for epidemiologic research. https://www.lifescience.mext.go.jp/files/pdf/n796_01.pdf. Accessed April 26 2020.
21. US Department of Health and Human Services. 45 CFR 46.116(d). <https://www.hhs.gov/ohrp/regulations-andpolicy/regulation/s/45-cfr-46/index.html#46.116>. Published 2009. Accessed May 26 2020.
22. Matsushita, M. *et al.* Association between the body mass index and the clinical findings in patients with acute heart failure: evaluation of the obesity paradox in patients with severely decompensated acute heart failure. *Heart Vessels* **32**, 600–608. <https://doi.org/10.1007/s00380-016-0908-9> (2017).
23. Curtis, J. P. *et al.* The obesity paradox: body mass index and outcomes in patients with heart failure. *Arch. Intern. Med.* **165**, 55–61. <https://doi.org/10.1001/archinte.165.1.55> (2005).
24. Shiraishi, Y. *et al.* 9-year trend in the management of acute heart failure in Japan: a report from the national consortium of acute heart failure registries. *J. Am. Heart Assoc.* **7**, e008687 (2018).
25. Coles, A. H. *et al.* Magnitude of and prognostic factors associated with 1-year mortality after hospital discharge for acute decompensated heart failure based on ejection fraction findings. *J. Am. Heart Assoc.* **4**, e002303. <https://doi.org/10.1161/JAHA.115.002303> (2015).
26. Okoshi, M. P., Capalbo, R. V., Romeiro, F. G. & Okoshi, K. Cardiac cachexia: perspectives for prevention and treatment. *Arq Bras Cardiol.* **108**, 74–80. <https://doi.org/10.5935/abc.20160142> (2017).
27. Curcio, F. *et al.* Sarcopenia and heart failure. *Nutrients* <https://doi.org/10.3390/nu12010211> (2020).
28. Yin, J., Lu, X., Qian, Z., Xu, W. & Zhou, X. New insights into the pathogenesis and treatment of sarcopenia in chronic heart failure. *Theranostics* **9**, 4019–4029 (2019).
29. Springer, J., Springer, J. I. & Anker, S. D. Muscle wasting and sarcopenia in heart failure and beyond: update 2017. *ESC Heart Fail.* **4**, 492–498. <https://doi.org/10.7150/thno.33000> (2017).
30. Takiguchi, M. *et al.* Impact of body mass index on mortality in heart failure patients. *Eur. J. Clin. Invest.* **44**, 1197–1205. <https://doi.org/10.1111/eci.12354> (2014).
31. Inoue, H. *et al.* Impact of body mass index on the prognosis of Japanese patients with non-valvular atrial fibrillation. *Am. J. Cardiol.* **118**, 215–221. <https://doi.org/10.1016/j.amjcard.2016.04.036> (2016).
32. Clark, A. L. *et al.* Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. *J. Cachexia Sarcopenia Muscle* **8**, 549–556. <https://doi.org/10.1002/jcsm.12191> (2017).
33. Vaz, M. *et al.* Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. *Circulation* **96**, 3423–3429. <https://doi.org/10.1161/01.cir.96.10.3423> (1997).
34. Weber, M. A., Neutel, J. M. & Smith, D. H. G. Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. *J. Am. Coll. Cardiol.* **37**, 169–174. [https://doi.org/10.1016/s0735-1097\(00\)01103-7](https://doi.org/10.1016/s0735-1097(00)01103-7) (2001).
35. Anker, S. D. *et al.* Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. *J. Am. Coll. Cardiol.* **30**, 997–1001. [https://doi.org/10.1016/s0735-1097\(97\)00262-3](https://doi.org/10.1016/s0735-1097(97)00262-3) (1997).
36. Yoshihisa, A. *et al.* Heterogeneous impact of body mass index on in-hospital mortality in acute heart failure syndromes: an analysis from the ATTEND Registry. *Eur. Heart J. Acute Cardiovasc. Care* **8**, 589–598. <https://doi.org/10.1177/2048872617703061> (2019).
37. Reddy, Y. N. V. *et al.* Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX Trial Ancillary Study. *Mayo Clin. Proc.* **94**, 1199–1209. <https://doi.org/10.1016/j.mayocp.2018.11.037> (2019).
38. Adamopoulos, C. *et al.* Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. *Eur. J. Heart Fail.* **13**, 200–206. <https://doi.org/10.1093/eurjhf/hfq159> (2011).
39. Nagarajan, V., Cauthen, C. A., Starling, R. C. & Tang, W. H. Prognosis of morbid obesity patients with advanced heart failure. *Congest Heart Fail.* **19**, 160–164. <https://doi.org/10.1111/chf.12038> (2013).
40. Hamaguchi, S. *et al.* Body mass index is an independent predictor of long-term outcomes in patients hospitalized with heart failure in Japan. *Circ. J.* **74**, 2605–2611. <https://doi.org/10.1253/circj.cj-10-0599> (2010).

Acknowledgments

The authors thank the staff of the KCHF study, the other members of the participating centers.

Author contributions

Y.Seko and T.Kato wrote the main manuscript text, table figure 1-4. Y.Seko, T.Kato and T.Morimoto conducted statistical analyses. Y.Seko, T.Kato, T.Morimoto, H.Y., Y.I., Y.T., N.O., M.S., E.Y., Y.Yoshikawa, Y. Yamashita, T.Kitai, R.T., M.I., K.N., T.Kawai, A.K., R.N., Y.K., T.Morinaga, M.T., Y.F., K.A., K.Kadota, Y.Sato, K.Kuwahara, T.Kimura acquired data. Y.Seko, T.Kato, T.Morimoto, H.Y., Y.I., Y.T., N.O., M.S., E.Y., Y.Yoshikawa, Y. Yamashita, T.Kitai, R.T., M.I., K.N., T.Kawai, A.K., R.N., Y.K., T.Morinaga, M.T., Y.F., K.A., K.Kadota, Y.Sato, K.Kuwahara, T.Kimura reviewed and revised manuscript critically.

Funding

This study was supported by grant 18059186 from the Japan Agency for Medical Research and Development (Drs T. Kato, Kuwahara, and Ozasa).

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41598-020-73640-w>.

Correspondence and requests for materials should be addressed to T.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020